Clinical trials
Lung Cancer, Non-Small Cell clinical trials
Below are recruiting lung cancer, non-small cell clinical trials, each written for real people, not researchers. We’re tracking 1,131 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05800340RecruitingPhase 2
Immunotherapy before surgery for certain rare lung cancer mutations
This Phase 2 study tests an immunotherapy treatment given before surgery for people with stage IIB to IIIB non-small cell lung cancer (NSCLC) that has specific rare “driver” gene changes. The goal is to shrink the cancer and improve outcomes by treating it earlier with the immune system.
Guanzhou, GuangdongAges 18 years+ - NCT05800587RecruitingPhase 2
Reduced-dose chemotherapy for advanced lung cancer
This trial studies a lower (reduced) dose of chemotherapy in people with advanced lung cancer who may not tolerate standard treatment. It aims to see if the treatment still works while being safer for “compromised” patients.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05802186Recruiting
AI-guided radiation plan for lung cancer tumors
This study uses an AI tool to help plan how doctors deliver focused radiation to lung tumors. It may help make radiation targeting more precise and support treatment safety for people with primary or limited metastatic lung cancer.
Chicago, IllinoisAges 18 years+ - NCT05805319Recruiting
Food intervention for people with lung cancer on immunotherapy
This trial studies whether a specific diet can help people with non-small cell lung cancer who are receiving immunotherapy (a standard cancer treatment). It mainly checks whether participants can follow the diet plan and tolerate the food changes safely.
Montreal, QuebecAges 18 years+ - NCT05819346Recruiting
Digital lifestyle program for lung cancer survivors
This trial tests a phone/tablet-based lifestyle program for people who have finished lung cancer treatment. It may help survivors improve health and daily habits after non-small cell lung cancer.
BarmelweidAges 18 years+ - NCT05830058RecruitingPhase 2
PET-guided focused radiation for limited worsening lung, melanoma, kidney cancer
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
Duarte, CaliforniaAges 18 years+ - NCT05835570Recruiting
PET scan using an integrin marker to find cancer
This trial uses a special PET/CT scan that targets a protein on some cancer cells to help detect and evaluate malignant tumors. It may help doctors better map tumors before any cancer treatment starts.
Wuhan, HubeiAges 18–85 - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Basking Ridge, New JerseyAges 18 years+ - NCT05837429Recruiting
Exercise training for early lung cancer survivors after surgery
This trial studies a low-time, high-intensity interval exercise program in people with non-small cell lung cancer who are stable and in remission after surgery. It may help improve fitness and recovery without requiring long exercise sessions.
Ankara, SıhhiyeAges 18–80 - NCT05849129RecruitingPhase 2
IV vitamin C added to first treatment for advanced lung cancer
This Phase 2 study tests whether adding an IV (into a vein) form of vitamin C (“ascorbic acid”) to standard first-line chemotherapy, with or without immunotherapy, can improve outcomes for people with stage IIIB/IV non-small cell lung cancer. You might benefit if the trial matches your cancer stage and upcoming treatment plan.
Ottawa, OntarioAges 18 years+ - NCT05852990RecruitingPhase 3
Gut help to prevent diarrhea from EGFR-targeted lung cancer drugs
This Phase 3 trial tests whether adding glutamine plus L. reuteri can help prevent severe diarrhea caused by EGFR-targeted treatments in people with advanced non-small cell lung cancer. If it works, it could make treatment easier to tolerate and help you stay on the planned therapy.
Mexico City, Mexico CityAges 18–80 - NCT05856981RecruitingPhase 1
Testing ADU-1805 for advanced solid tumors safety
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Detroit, MichiganAges 18 years+ - NCT05864794Recruiting
Screening brain MRI in advanced lung cancer patients
This trial looks at whether doing an MRI scan of the brain for people with stage IV lung cancer helps in their care. The goal is to find brain issues early (if present) so treatment decisions can be made sooner.
Groningen, Provincie GroningenAges 18 years+ - NCT05885698Recruiting
Study of care patterns in newly diagnosed lung cancer
This observational study follows adults with newly diagnosed non-small cell lung cancer to understand what treatments are used and how patients are doing. It may help doctors better understand how care decisions affect outcomes, and it does not require the study to give an experimental treatment.
Daphne, AlabamaAges 18 years+ - NCT05886439RecruitingPhase 1/Phase 2
Study drug plus PD-1 or PD-L1 for lung cancer
This Phase 1/2 trial tests a new treatment called LK101 combined with a PD-1 or PD-L1 antibody for advanced lung cancer. It may help shrink tumors and improve control of the disease, especially after prior anti–PD-1/PD-L1 treatment has stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT05913089RecruitingPhase 2
Testing a new lung cancer drug with chemotherapy or an anti-angiogenesis pill
This Phase 2 trial tests TQB2450 (a new cancer medicine) added to chemotherapy, or along with an oral medicine called anlotinib, for stage II–IIIB non-small cell lung cancer. It may help shrink tumors and improve outcomes in people who are getting curative surgery and have not had prior cancer drug treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT05922345RecruitingPhase 3
Study drug vs docetaxel for advanced lung cancer after prior treatment
This Phase 3 trial compares AL2846 pills plus TQB2450 injections against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer. You may qualify if your cancer has progressed after platinum chemotherapy and immunotherapy, and if certain tumor genetic tests are negative.
Hefei, AnhuiAges 18–75 - NCT05933239RecruitingPhase 2
PET-like scan using a special protein in lung cancer
This Phase 2 study tests whether a new imaging medicine (a radiopharmaceutical) can highlight immune cells called macrophages in people with non-small cell lung cancer. It may help doctors better “see” and evaluate tumor tissue before a surgical biopsy or removal.
Jette, Brussels CapitalAges 18 years+ - NCT05935384Recruiting
Blood tests to track response to cancer therapy
This study follows how cancer responds to standard (usual) treatment by using blood samples and de-identified health data. It may help researchers understand whether “liquid biopsy” blood testing can reflect how well therapy is working.
Skokie, IllinoisAges 18 years+ - NCT05940532RecruitingPhase 2
Sutimab plus chemotherapy for advanced lung cancer needing radiation
This trial tests a cancer-fighting antibody (sugemalimab) added to standard chemotherapy for stage III lung cancer that can’t be removed by surgery but may be treated with radiation. It aims to improve control of your cancer while checking safety and side effects.
ChangshaAges 18–75 - NCT05949606RecruitingPhase 1/Phase 2
New study for advanced lung cancer using two antibody drugs
This Phase 1/2 trial tests whether two antibody drugs (SI-B001 and SI-B003) work well for locally advanced or metastatic non-small cell lung cancer, sometimes together with chemotherapy. It may help shrink tumors and control the disease, while closely monitoring safety and side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05956587RecruitingPhase 2
Testing two study drugs for advanced lung cancer and other tumors
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
Chongqing, Chongqing MunicipalityAges 18–75
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer, non-small cell?
- Yes. Clin2 currently lists 1,131 recruiting lung cancer, non-small cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer, non-small cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer, non-small cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.